Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR8613742

— · A

18aec5bb-87eb-5b5c-b7fc-fe1937e6773b

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
A
subtype
A

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • UV_RESPONSE_DN+0.440
  • ANGIOGENESIS+0.370
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.340
  • COAGULATION+0.310
  • MYOGENESIS+0.310
  • PANCREAS_BETA_CELLS+0.310
  • KRAS_SIGNALING_UP+0.240
  • COMPLEMENT+0.220
  • HEDGEHOG_SIGNALING+0.200
  • XENOBIOTIC_METABOLISM+0.200

Top 10 suppressed

  • MYC_TARGETS_V2-0.700
  • E2F_TARGETS-0.680
  • MYC_TARGETS_V1-0.620
  • G2M_CHECKPOINT-0.610
  • MTORC1_SIGNALING-0.530
  • UNFOLDED_PROTEIN_RESPONSE-0.480
  • DNA_REPAIR-0.410
  • MITOTIC_SPINDLE-0.410
  • OXIDATIVE_PHOSPHORYLATION-0.380
  • GLYCOLYSIS-0.350

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR8518451
breast-umap@18
—A0.915
2SRR8518299
breast-umap@18
—A0.906
3TCGA-G2-A2EC-01A-11R-A180-07
bladder-landscape@3
——0.895
4DRR168582
bladder-landscape@3
——0.892
520040019.LumA
breast-umap@18
—A0.886
6C3L-02893
lung-landscapes@6
—cohortA10.881
7TCGA-55-8096-01A-11R-2241-07
lung-landscapes@6
—cohortA10.877
8TCGA-AC-A2FF-01A-11R-A17B-07
breast-umap@18
—A0.876
9C3N-03911
lung-landscapes@6
—cohortA10.874
10C3L-03268
lung-landscapes@6
—cohortA10.873

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 23 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
UV_RESPONSE_DN0.440Inavolisib— uncovered
ANGIOGENESIS0.370Remibrutinib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.340Inavolisib— uncovered
COAGULATION0.310Binimetinib— uncovered
MYOGENESIS0.310Inavolisib— uncovered
PANCREAS_BETA_CELLS0.310Cobimetinib— uncovered
KRAS_SIGNALING_UP0.240Inavolisib— uncovered
COMPLEMENT0.220Inavolisib— uncovered
HEDGEHOG_SIGNALING0.200Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.200Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.180Inavolisib— uncovered
BILE_ACID_METABOLISM0.160Inavolisib— uncovered
ADIPOGENESIS0.120Inavolisib— uncovered
HEME_METABOLISM0.110Temsirolimus— uncovered
IL2_STAT5_SIGNALING0.110Idelalisib— uncovered
APICAL_JUNCTION0.100Inavolisib— uncovered
APICAL_SURFACE0.080Temsirolimus— uncovered
FATTY_ACID_METABOLISM0.060Inavolisib— uncovered
KRAS_SIGNALING_DN0.060Remibrutinib— uncovered
INFLAMMATORY_RESPONSE0.050Idelalisib— uncovered